MX390747B - Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. - Google Patents
Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.Info
- Publication number
- MX390747B MX390747B MX2019003143A MX2019003143A MX390747B MX 390747 B MX390747 B MX 390747B MX 2019003143 A MX2019003143 A MX 2019003143A MX 2019003143 A MX2019003143 A MX 2019003143A MX 390747 B MX390747 B MX 390747B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- preparation
- alkynyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 108091008794 FGF receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610833890.3A CN107840842A (zh) | 2016-09-19 | 2016-09-19 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
| PCT/CN2017/072570 WO2018049781A1 (zh) | 2016-09-19 | 2017-01-25 | 炔代杂环化合物、其制备方法及其在医药学上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003143A MX2019003143A (es) | 2019-06-17 |
| MX390747B true MX390747B (es) | 2025-03-21 |
Family
ID=61618562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003143A MX390747B (es) | 2016-09-19 | 2017-01-25 | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10710981B2 (enExample) |
| EP (1) | EP3517535B1 (enExample) |
| JP (1) | JP6906811B2 (enExample) |
| KR (1) | KR102783517B1 (enExample) |
| CN (2) | CN107840842A (enExample) |
| AU (1) | AU2017327954B2 (enExample) |
| CA (1) | CA3036594C (enExample) |
| ES (1) | ES2925212T3 (enExample) |
| MX (1) | MX390747B (enExample) |
| RU (1) | RU2729069C1 (enExample) |
| SG (1) | SG10202102822RA (enExample) |
| WO (1) | WO2018049781A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020120673A1 (en) * | 2018-12-13 | 2020-06-18 | Intervet International B.V. | Process for preparing 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]p yrazole-4-carboxamide |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| AU2020412067A1 (en) * | 2019-12-26 | 2022-08-11 | Beijing Innocare Pharma Tech Co., Ltd. | Crystalline forms of (S) -1- (1-acryloylpyrrolidin-3-yl) -3- ( (3, 5-dimethoxyphenyl) ethynyl) -5- (methylamino) -1H-pyrazole-4-carboxamide |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN116057045A (zh) * | 2020-06-05 | 2023-05-02 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶抑制剂 |
| CN116096707A (zh) * | 2020-06-05 | 2023-05-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶的抑制剂 |
| WO2022042613A1 (zh) * | 2020-08-27 | 2022-03-03 | 上海和誉生物医药科技有限公司 | 一种1h-吡唑-4-酰胺衍生物，其制备方法和应用 |
| CA3204407A1 (en) * | 2021-01-12 | 2022-07-21 | Yucheng PANG | Process for preparing (s)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl) ethynyl)-5-(methylamino)-1h-pyrazole-4-carboxamide |
| CN115433190B (zh) * | 2021-06-02 | 2024-09-20 | 药雅科技(上海)有限公司 | 不可逆杂环化合物fgfr抑制剂的制备方法和用途 |
| CN114853739B (zh) * | 2021-02-03 | 2023-09-22 | 药雅科技(上海)有限公司 | 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途 |
| CN115043832B (zh) * | 2021-03-08 | 2023-08-22 | 药雅科技(上海)有限公司 | 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途 |
| JP2024539723A (ja) * | 2021-11-03 | 2024-10-29 | ベイジン・イノケア・ファーマ・テク・カンパニー・リミテッド | （ｓ）－１－（１－アクリロイルピロリジン－３－イル）－３－（（３，５－ジメトキシフェニル）エチニル）－５－（メチルアミノ）－１ｈ－ピラゾール－４－カルボキサミドを含む非晶質固体分散体 |
| CA3238193A1 (en) * | 2021-11-16 | 2023-05-25 | Jisong Cui | Method for treating head and neck cancer |
| KR20240119095A (ko) * | 2021-12-08 | 2024-08-06 | 킨네이트 바이오파마 인크. | Fgfr 저해제의 고체 상태 형태 |
| WO2023107870A1 (en) * | 2021-12-08 | 2023-06-15 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| EP4444713A4 (en) * | 2021-12-08 | 2025-08-06 | Kinnate Biopharma Inc | CANCER TREATMENT WITH AN FGFR KINASE INHIBITOR |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| KR101124245B1 (ko) | 2002-06-27 | 2012-07-02 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
| CN1508130A (zh) | 2002-12-18 | 2004-06-30 | 中国科学院大连化学物理研究所 | N-苯基-n’-嘧啶基取代脲类衍生物的合成方法 |
| US7150894B2 (en) * | 2003-05-01 | 2006-12-19 | Kraft Foods Holdings, Inc. | Acid whey texture system |
| ATE400567T1 (de) | 2004-06-23 | 2008-07-15 | Lilly Co Eli | Kinaseinhibitoren |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2007059341A2 (en) | 2005-11-16 | 2007-05-24 | Sgx Pharmaceuticals, Inc. | Pyrazolothiazole protein kinase modulators |
| FR2908409B1 (fr) | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| CN101611014B (zh) * | 2006-12-21 | 2012-05-30 | 阿斯利康(瑞典)有限公司 | 用作fgfr抑制剂的酰氨基吡唑类化合物 |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| DK2959900T3 (en) | 2008-06-16 | 2017-06-26 | Univ Tennessee Res Found | CONNECTION TO TREATMENT OF CANCER |
| FR2947546B1 (fr) | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| CN102883607B (zh) * | 2010-03-01 | 2015-07-22 | Gtx公司 | 用于治疗癌的化合物 |
| JP6016915B2 (ja) * | 2011-07-28 | 2016-10-26 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性なアルキニル置換ピリミジニルピロール |
| WO2013024427A1 (en) | 2011-08-16 | 2013-02-21 | Glenmark Pharmaceuticals S.A. | Novel urea derivatives as tec kinase inhibitors and uses thereof |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| PT3023100T (pt) * | 2013-07-18 | 2019-05-29 | Taiho Pharmaceutical Co Ltd | Fármaco antitumoral para administração intermitente de inibidor de fgfr |
| ES2819398T3 (es) * | 2013-07-18 | 2021-04-15 | Taiho Pharmaceutical Co Ltd | Agente terapéutico para el cáncer resistente al inhibidor de FGFR |
| AU2014338549B2 (en) | 2013-10-25 | 2017-05-25 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors |
| JP6695353B2 (ja) | 2015-03-25 | 2020-05-20 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 |
-
2016
- 2016-09-19 CN CN201610833890.3A patent/CN107840842A/zh not_active Withdrawn
-
2017
- 2017-01-25 ES ES17849992T patent/ES2925212T3/es active Active
- 2017-01-25 RU RU2019112046A patent/RU2729069C1/ru active
- 2017-01-25 CN CN201780057036.5A patent/CN109843873B/zh active Active
- 2017-01-25 SG SG10202102822RA patent/SG10202102822RA/en unknown
- 2017-01-25 EP EP17849992.7A patent/EP3517535B1/en active Active
- 2017-01-25 CA CA3036594A patent/CA3036594C/en active Active
- 2017-01-25 JP JP2019515464A patent/JP6906811B2/ja active Active
- 2017-01-25 KR KR1020197011454A patent/KR102783517B1/ko active Active
- 2017-01-25 AU AU2017327954A patent/AU2017327954B2/en active Active
- 2017-01-25 MX MX2019003143A patent/MX390747B/es unknown
- 2017-01-25 WO PCT/CN2017/072570 patent/WO2018049781A1/zh not_active Ceased
-
2019
- 2019-03-14 US US16/353,806 patent/US10710981B2/en active Active
-
2020
- 2020-07-10 US US16/925,738 patent/US11059805B2/en active Active
-
2021
- 2021-07-07 US US17/369,850 patent/US11572353B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109843873B (zh) | 2022-06-17 |
| MX2019003143A (es) | 2019-06-17 |
| WO2018049781A1 (zh) | 2018-03-22 |
| EP3517535A1 (en) | 2019-07-31 |
| JP2019529444A (ja) | 2019-10-17 |
| ES2925212T3 (es) | 2022-10-14 |
| US20190210997A1 (en) | 2019-07-11 |
| EP3517535B1 (en) | 2022-06-29 |
| CN109843873A (zh) | 2019-06-04 |
| US20200339541A1 (en) | 2020-10-29 |
| JP6906811B2 (ja) | 2021-07-21 |
| CA3036594C (en) | 2024-02-13 |
| AU2017327954B2 (en) | 2022-02-03 |
| AU2017327954A1 (en) | 2019-05-02 |
| EP3517535A4 (en) | 2020-02-26 |
| US11059805B2 (en) | 2021-07-13 |
| US10710981B2 (en) | 2020-07-14 |
| RU2729069C1 (ru) | 2020-08-04 |
| KR20190052113A (ko) | 2019-05-15 |
| US11572353B2 (en) | 2023-02-07 |
| US20210332027A1 (en) | 2021-10-28 |
| CN107840842A (zh) | 2018-03-27 |
| SG10202102822RA (en) | 2021-05-28 |
| CA3036594A1 (en) | 2018-03-22 |
| KR102783517B1 (ko) | 2025-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| SA520420033B1 (ar) | مركبات صيدلية | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| PH12018500904A1 (en) | Peptide macrocycles against acinetobacter baumannii | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX394082B (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de cinasa pim. | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX377845B (es) | Inhibidores de calicreína plasmática humana. | |
| MX2024009886A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
| EA201690848A1 (ru) | Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4 | |
| EA201790660A1 (ru) | Ингибитор киназ | |
| MX2021003655A (es) | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| EA201692003A1 (ru) | Макроциклические производные пиримидина | |
| EA201990833A1 (ru) | Соединение пиридина | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| MX381041B (es) | Compuesto cíclico tipo cumarina como inhibidor de mek y su uso. | |
| EA201692000A1 (ru) | Макроциклические производные пиридина | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| EA201692300A1 (ru) | Производные карбоксамида |